Tipelukast
- Generic Name
- Tipelukast
- Drug Type
- Small Molecule
- Chemical Formula
- C29H38O7S
- CAS Number
- 125961-82-2
- Unique Ingredient Identifier
- 08379P260O
- Background
Tipelukast is under investigation for the treatment of IPF and Idiopathic pulmonary fibrosis.
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
- Conditions
- Non-Alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2Hypertriglyceridemia
- Interventions
- Drug: MN-001 placebo
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 40
- Registration Number
- NCT05464784
- Locations
- 🇺🇸
Pinnacle Clinical Research at South Texas Research Institute, Edinburg, Texas, United States
🇺🇸Jubilee Clinical Research, Inc., Las Vegas, Nevada, United States
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
- Conditions
- Non-alcoholic SteatohepatitisHypertriglyceridemiaNon-alcoholic Fatty Liver DiseaseHypercholesterolemia
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 19
- Registration Number
- NCT02681055
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Scripps Research, La Jolla, California, United States
🇺🇸Harborview Medical Center, Seattle, Washington, United States
Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- Conditions
- Idiopathic Pulmonary FibrosisIPF
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 15
- Registration Number
- NCT02503657
- Locations
- 🇺🇸
Penn State University College of Medicine, Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
- Conditions
- Interstitial Cystitis
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- MediciNova
- Target Recruit Count
- 296
- Registration Number
- NCT00295854
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸Adult and Pediatric Urology, Plantation, Florida, United States
🇺🇸Georgis Patsias, MD., PA, Wellington, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.